Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 4/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.75 |
| ▸ | ACKR3 | P25106 | 7/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.48 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.48 |
| ▸ | GRK5 | P34947 | 1/20 | 0.48 |
| ▸ | CDK8 | P49336 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2845543 | 1.00 | CACNA1B (0.75) | CACNA1BKCNH2ACKR3SIGMAR1S1PR1 | |
| SCHEMBL2845542 | 1.00 | CACNA1B (0.75) | CACNA1BKCNH2ACKR3SIGMAR1S1PR1 | |
| SCHEMBL2845507 | 1.00 | CACNA1B (0.75) | CACNA1BKCNH2ACKR3SIGMAR1S1PR1 | |
| SCHEMBL2845395 | 0.99 | CACNA1B (0.74) | CACNA1BKCNH2ACKR3SIGMAR1S1PR1 | |
| SCHEMBL2845391 | 0.99 | CACNA1B (0.74) | CACNA1BKCNH2ACKR3SIGMAR1S1PR1 | |
| SCHEMBL65951 | 0.86 | CACNA1B (1.00) | CACNA1BKCNH2ACKR3SIGMAR1S1PR1 | |
| SCHEMBL67278 | 0.86 | CACNA1B (1.00) | CACNA1BKCNH2ACKR3SIGMAR1S1PR1 | |
| SCHEMBL66902 | 0.86 | CACNA1B (1.00) | CACNA1BKCNH2ACKR3SIGMAR1S1PR1 | |
| SCHEMBL66974 | 0.86 | CACNA1B (1.00) | CACNA1BKCNH2ACKR3SIGMAR1S1PR1 | |
| SCHEMBL16498056 | 0.86 | CACNA1B (0.72) | CACNA1BKCNH2SIGMAR1S1PR1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130558-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-05-27 | — | — | US | claimed |
| US-20100130558-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130558-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, ORAI1, CACNA1S | CACNA1B 5/4885KCNH2 24/4885ACKR3 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.